S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Modern Day Options Trading For Beginners! (Ad)pixel
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
"Prepare for Five Years of Famine" (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
"Prepare for Five Years of Famine" (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Modern Day Options Trading For Beginners! (Ad)pixel
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
"Prepare for Five Years of Famine" (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
"Prepare for Five Years of Famine" (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Modern Day Options Trading For Beginners! (Ad)pixel
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
"Prepare for Five Years of Famine" (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
"Prepare for Five Years of Famine" (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Modern Day Options Trading For Beginners! (Ad)pixel
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
"Prepare for Five Years of Famine" (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
"Prepare for Five Years of Famine" (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
NASDAQ:OPRX

OptimizeRx - OPRX Stock Forecast, Price & News

$14.06
-0.08 (-0.57%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$13.95
$14.62
50-Day Range
$12.54
$19.38
52-Week Range
$12.20
$42.30
Volume
222,606 shs
Average Volume
273,266 shs
Market Capitalization
$240.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.43

OptimizeRx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
95.1% Upside
$27.43 Price Target
Short Interest
Bearish
8.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.69mentions of OptimizeRx in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.66) to ($0.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Computer And Technology Sector

207th out of 614 stocks

Business Services, Not Elsewhere Classified Industry

33rd out of 93 stocks


OPRX stock logo

About OptimizeRx (NASDAQ:OPRX) Stock

OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell on November 8, 1985 and is headquartered in Rochester, MI.

Receive OPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter.

OPRX Stock News Headlines

Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
OptimizeRx Corp. (OPRX) Q4 Earnings Beat Estimates
Should You Buy OptimizeRx (OPRX) Ahead of Earnings?
OptimizeRx to Participate in Upcoming Investor Conferences
OptimizeRx Corp. (OPRX) Tops Q3 Earnings Estimates
OptimizeRx Reports Third Quarter 2022 Financial Results
See More Headlines
Receive OPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter.

OPRX Company Calendar

Last Earnings
11/09/2021
Today
3/28/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Business services, not elsewhere classified
Sub-Industry
N/A
Current Symbol
NASDAQ:OPRX
Employees
97
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.43
High Stock Price Forecast
$66.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+95.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-11,440,000.00
Pretax Margin
-18.32%

Debt

Sales & Book Value

Annual Sales
$62.45 million
Book Value
$7.35 per share

Miscellaneous

Free Float
16,502,000
Market Cap
$240.43 million
Optionable
Not Optionable
Beta
1.04

Key Executives

  • Will Febbo
    Chief Executive Officer & Director
  • Edward Stelmakh
    Chief Operations & Financial Officer
  • Todd Inman
    Chief Technology Officer
  • Marion K. Odence-Ford
    Chief Compliance Officer & General Counsel
  • Angelo Campano
    Senior Vice President & Principal-Agency Channels













OPRX Stock - Frequently Asked Questions

Should I buy or sell OptimizeRx stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OPRX shares.
View OPRX analyst ratings
or view top-rated stocks.

What is OptimizeRx's stock price forecast for 2023?

7 brokerages have issued 1-year price objectives for OptimizeRx's stock. Their OPRX share price forecasts range from $16.00 to $66.00. On average, they anticipate the company's share price to reach $27.43 in the next year. This suggests a possible upside of 95.1% from the stock's current price.
View analysts price targets for OPRX
or view top-rated stocks among Wall Street analysts.

How have OPRX shares performed in 2023?

OptimizeRx's stock was trading at $16.80 at the beginning of 2023. Since then, OPRX stock has decreased by 16.3% and is now trading at $14.06.
View the best growth stocks for 2023 here
.

When is OptimizeRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our OPRX earnings forecast
.

How were OptimizeRx's earnings last quarter?

OptimizeRx Co. (NASDAQ:OPRX) issued its quarterly earnings results on Tuesday, November, 9th. The company reported $0.09 earnings per share for the quarter, missing analysts' consensus estimates of $0.13 by $0.04. The business earned $16.13 million during the quarter, compared to the consensus estimate of $14.82 million. OptimizeRx had a negative trailing twelve-month return on equity of 7.12% and a negative net margin of 18.30%. During the same quarter in the previous year, the company earned ($0.01) earnings per share.

What ETFs hold OptimizeRx's stock?
What guidance has OptimizeRx issued on next quarter's earnings?

OptimizeRx updated its first quarter 2023 earnings guidance on Wednesday, March, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $11.50 million-$13.00 million, compared to the consensus revenue estimate of $16.15 million.

What other stocks do shareholders of OptimizeRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN).

What is OptimizeRx's stock symbol?

OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX."

Who are OptimizeRx's major shareholders?

OptimizeRx's stock is owned by many different institutional and retail investors. Top institutional investors include Blair William & Co. IL (4.76%), First Light Asset Management LLC (2.11%), Credit Suisse AG (1.94%), Geode Capital Management LLC (1.84%), Kornitzer Capital Management Inc. KS (1.75%) and Rice Hall James & Associates LLC (1.58%). Insiders that own company stock include Douglas P Baker, Douglas P Baker, Edward Stelmakh, Ellen O'connor Vos, Gregory D Wasson, James Paul Lang, Marion Odence-Ford, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, Stephen L Silvestro and William J Febbo.
View institutional ownership trends
.

How do I buy shares of OptimizeRx?

Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OptimizeRx's stock price today?

One share of OPRX stock can currently be purchased for approximately $14.06.

How much money does OptimizeRx make?

OptimizeRx (NASDAQ:OPRX) has a market capitalization of $240.43 million and generates $62.45 million in revenue each year. The company earns $-11,440,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis.

How can I contact OptimizeRx?

OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The official website for the company is www.optimizerx.com. The company can be reached via phone at (248) 651-6568, via email at oprx@cma.team, or via fax at 248-453-5529.

This page (NASDAQ:OPRX) was last updated on 3/28/2023 by MarketBeat.com Staff